文献速递银屑病与炎症性皮肤病

替拉珠单抗治疗中重度头皮斑块状银屑病52周疗效与安全性

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial.
PubMed 文献 · J Am Acad Dermatol · 2024-12-23

这项3b期随机双盲安慰剂对照研究评估替拉珠单抗治疗中重度头皮斑块状银屑病至第52周的疗效与安全性。替拉珠单抗组第16周至第52周头皮IGA 0/1应答率由49.4%升至62.9%,PSSI≥90%应答率由60.7%升至65.2%,超过80%的第16周应答者维持应答,未发生治疗相关严重不良事件。

要点

  • 替拉珠单抗100mg每12周治疗头皮银屑病至52周疗效持续。
  • 第52周头皮IGA 0/1和PSSI≥90%应答率分别为62.9%和65.2%。
  • 超过80%的第16周应答者在第52周维持应答。

核心结论

  • 替拉珠单抗治疗中重度头皮斑块状银屑病的疗效和安全性可长期维持。

研究设计与样本

  • 3b期随机双盲安慰剂对照研究(NCT03897088),替拉珠单抗组继续100mg每12周,安慰剂组第16周换用替拉珠单抗100mg并单独分析。

主要发现

  • 替拉珠单抗组与安慰剂组头皮IGA 0/1应答率从第16周的49.4%对7.3%升至第52周的62.9%对56.1%。
  • 替拉珠单抗组与安慰剂组PSSI≥90%应答率从第16周的60.7%对4.9%升至第52周的65.2%对57.3%。
  • 超过80%的第16周替拉珠单抗应答者在第52周维持应答,未发生治疗相关严重不良事件。

关键数值与推荐

  • 疗效终点包括头皮IGA modified 2011评分0或1且较基线改善≥2级,以及PSSI较基线改善≥90%。

临床怎么用

  • 替拉珠单抗100mg每12周可用于中重度头皮斑块状银屑病的长期治疗。

局限性

  • 结果来自受控临床试验条件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the primary analysis of a phase 3b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe plaque psoriasis affecting the scalp (NCT03897088), tildrakizumab, an anti-interleukin-23 p19 antibody, met the primary efficacy endpoint at week 16. OBJECTIVE: To evaluate maintenance of tildrakizumab efficacy and safety for the treatment of scalp psoriasis from the week 52 full analysis. METHODS: Patients randomized to tildrakizumab continued receiving tildrakizumab 100 mg every 12 weeks; patients randomized to placebo (analyzed separately) switched to tildrakizumab 100 mg at week 16. Efficacy endpoints included Investigator Global Assessment modified 2011 (scalp) score of 0 or 1 with ≥2-grade improvement and ≥90% improvement in Psoriasis Scalp Severity Index score from baseline. Safety was assessed from adverse events. RESULTS: In patients originally randomized to tildrakizumab versus placebo, Investigator Global Assessment modified 2011 (scalp) and ≥90% improvement in Psoriasis Scalp Severity Index score response rates, respectively, improved from 49.4% versus 7.3% and 60.7% versus 4.9% at week 16 to 62.9% versus 56.1% and 65.2% versus 57.3% at week 52; >80% of week 16 responders to tildrakizumab maintained response. No treatment-related serious adverse events occurred. LIMITATIONS: Results were obtained under controlled clinical conditions. CONCLUSION: Efficacy and safety of tildrakizumab for the treatment of scalp psoriasis are sustained long-term.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Sofen HL, Gebauer K, Spelman L, et al. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024. PMID: 39722400. doi:10.1016/j.jaad.2024.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。